{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:09:40Z","timestamp":1791554980542,"version":"4.3.4"},"reference-count":17,"publisher":"Oceanside Publications Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:p>Hereditary angioedema (HAE) is a rare disorder caused by genetic mutations that lead to recurrent episodes of swelling in various parts of the body. Prophylactic treatment is common for patients with HAE, and the therapeutic options have expanded in recent years. The current standard of care for prophylactic HAE therapies is subcutaneous treatment, which can be self-administered at home, greatly improving patient quality of life. As new therapies emerge, it is important for patients and physicians to discuss the risks and benefits associated with each treatment to develop an individualized approach to HAE management. We conducted surveys of patients with HAE and physicians who treat patients with HAE to identify prescribing trends for prophylactic HAE treatments and the impact that such treatments has on patients. Our results confirmed that newer, subcutaneous therapies are prescribed for HAE prophylaxis more frequently than other therapies in the United States and that treatment burdens still exist for patients with HAE. We found that physicians and patients were not always aligned on how treatment choices affect patients\u2019 lives, which may mean that there are opportunities for enhanced patient\u2010physician dialog and shared decision-making in HAE management in the United States.<\/jats:p>","DOI":"10.2500\/aap.2021.42.210017","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T04:37:15Z","timestamp":1620880635000},"page":"S17-S25","source":"Crossref","is-referenced-by-count":30,"title":["Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs"],"prefix":"10.2500","volume":"42","author":[{"given":"Marc A.","family":"Riedl","sequence":"first","affiliation":[{"name":"From the Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California, San Diego, La Jolla, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Craig","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pediatrics, Penn State University, Hershey Medical Center, Hershey, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[{"name":"Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., Durham, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Best","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., Durham, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinky","family":"Rosselli","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., Durham, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hahn","sequence":"additional","affiliation":[{"name":"KJT Group, Inc., Honeoye Falls, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Radojicic","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","article-title":"Hereditary angioedema: an update on causes, manifestations and treatment","volume":"80","author":"Longhurst","year":"2019","journal-title":"Br J Hosp Med (Lond)"},{"key":"B2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/14712598.2019.1595581","article-title":"Current and emerging biologics for the treatment of hereditary angioedema","volume":"19","author":"Perego","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B3","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.2500\/aap.2020.41.200092","article-title":"Hereditary angioedema: long-term prophylactic treatment","volume":"41(","author":"Li","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.anai.2020.10.009","article-title":"Current medical management of hereditary angioedema: follow-up survey of US physicians","volume":"126","author":"Riedl","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.2500\/aap.2020.41.200057","article-title":"Hereditary angioedema and shared decision making","volume":"41(","author":"Settipane","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B7","doi-asserted-by":"crossref","first-page":"e0170055","DOI":"10.1371\/journal.pone.0170055","article-title":"Impact of adding a decision aid to patient education in adults with asthma: a randomized clinical trial","volume":"12","author":"Gagn\u00e9","year":"2017","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00013","article-title":"The benefits and challenges of using patient decision aids to support shared decision making in health care","volume":"2","author":"Ankolekar","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"B9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11886-016-0729-6","article-title":"Shared decision-making and patient empowerment in preventive cardiology","volume":"18","author":"Kambhampati","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"B10","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2500\/aap.2021.42.210025","article-title":"Patient perspectives on the treatment burden of injectable medication for hereditary angioedema","volume":"42(Suppl 1)","author":"Radojicic","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/0145721709345773","article-title":"Barriers to insulin injection therapy: patient and health care provider perspectives","volume":"35","author":"Rubin","year":"2009","journal-title":"Diabetes Educ"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/PPA.S198953","article-title":"Patient and physician preferences for attributes of biologic medications for severe asthma","volume":"13","author":"Gelhorn","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"B13","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.3390\/ijms21218242","article-title":"Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches","volume":"21","author":"Ricci","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/nop2.194","article-title":"Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema","volume":"6","author":"Murphy","year":"2018","journal-title":"Nurs Open"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jaip.2017.12.039","article-title":"Health-related quality of life with subcutaneous C1-inhibitor for prevention of attacks of hereditary angioedema","volume":"6","author":"Lumry","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","article-title":"Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study","author":"Lumry","year":"2020","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/JAA.S284029","article-title":"Optimal management of hereditary angioedema: shared decision-making","volume":"14","author":"Banerji","year":"2021","journal-title":"J Asthma Allergy"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2021\/00000042\/a00103s1\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T06:08:53Z","timestamp":1672121333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2021.42.210017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5,1]]}},"alternative-id":["1088-5412(20210501)42:3+L.17;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2021.42.210017","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}